Brain Oligometastatic, Non-small Cell Lung Cancer
Conditions
Keywords
Metastatic NSCLC, Brain metastasis, Oligometastasis, Survival
Brief summary
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute
Detailed description
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.
Interventions
OTHERStandard treatments / multiple strategies
Standard treatments / multiple strategies
Sponsors
University Hospital, Bordeaux
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Consecutive patients managed at Bordeaux University Hospital * Non-small-cell lung cancer * Oligometastatic brain cancer (fewer than 5 lesions at diagnosis) * Patient over 18 years old
Exclusion criteria
* Oncogenic addiction EGFR, ALK, ROS1 * Patient with concomitant cancer * Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | Once, at progression or death from any cause | Time from random assignment in a clinical trial to disease progression or death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS from the date of the next treatment to disease progression or death from any cause (PFS2) | Once, at progression or death from any cause | PFS from the date of the next treatment to disease progression or death from any cause |
| Overall survival (OS) | Once, death from any cause or lost of follow-up | Time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive |
Countries
France
Outcome results
None listed